These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 13130101)

  • 1. Selection bias, phase II trials, and the FDA accelerated approval process.
    George SL
    J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
    [No Abstract]   [Full Text] [Related]  

  • 2. More haste, less speed.
    Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
    [No Abstract]   [Full Text] [Related]  

  • 3. Despite concerns, FDA panel backs EGFR inhibitor.
    Twombly R
    J Natl Cancer Inst; 2002 Nov; 94(21):1596-7. PubMed ID: 12419780
    [No Abstract]   [Full Text] [Related]  

  • 4. Gefitinib does not increase survival in lung cancer patients.
    Golsteyn RM
    Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
    [No Abstract]   [Full Text] [Related]  

  • 5. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R
    J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer drugs. Smart weapons prove tough to design.
    Couzin J
    Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
    [No Abstract]   [Full Text] [Related]  

  • 7. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Kazandjian D; Blumenthal GM; Yuan W; He K; Keegan P; Pazdur R
    Clin Cancer Res; 2016 Mar; 22(6):1307-12. PubMed ID: 26980062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demand grows for early access to promising cancer drugs.
    Baldwin J
    J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
    [No Abstract]   [Full Text] [Related]  

  • 10. Gefitinib Approved for EGFR-Mutated NSCLC.
    Cancer Discov; 2015 Sep; 5(9):896. PubMed ID: 26238462
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 12. Model aims to reduce discrepancy between phase II, phase III trials.
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1554-5, 1556. PubMed ID: 11018083
    [No Abstract]   [Full Text] [Related]  

  • 13. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 14. Iressa failure raises fears about accelerated approvals.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15756753
    [No Abstract]   [Full Text] [Related]  

  • 15. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
    Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
    [No Abstract]   [Full Text] [Related]  

  • 16. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
    McBride D
    ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA announces fast track approval of new drug for lung cancer.
    Dyer O
    BMJ; 2003 May; 326(7397):1004. PubMed ID: 12742913
    [No Abstract]   [Full Text] [Related]  

  • 20. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
    Jänne PA
    J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.